MDT-AP-0830
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 120
- os_event
- false
- age_years
- 11
- sex
- M
- new_clusters
- C3
- umap1_2d
- 5.99994429
- umap2_2d
- 3.775237626
- umap1_3d
- 2.847394636
- umap2_3d
- -2.444889888
- umap3_3d
- -3.065593838
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.280
- WNT_BETA_CATENIN_SIGNALING+0.270
- HEME_METABOLISM+0.120
- NOTCH_SIGNALING+0.090
- KRAS_SIGNALING_DN-0.020
- PI3K_AKT_MTOR_SIGNALING-0.040
- APICAL_JUNCTION-0.060
- GLYCOLYSIS-0.060
- HEDGEHOG_SIGNALING-0.060
- MYOGENESIS-0.080
Top 10 suppressed
- E2F_TARGETS-0.590
- MYC_TARGETS_V1-0.540
- G2M_CHECKPOINT-0.520
- ANDROGEN_RESPONSE-0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- TNFA_SIGNALING_VIA_NFKB-0.390
- MTORC1_SIGNALING-0.380
- INFLAMMATORY_RESPONSE-0.360
- APOPTOSIS-0.350
- ALLOGRAFT_REJECTION-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0393 | Med | Medulloblastoma | 0.948 |
| 2 | MDT-AP-0734 | Med | Medulloblastoma | 0.916 |
| 3 | MDT-AP-0376 | Med | Medulloblastoma | 0.906 |
| 4 | MDT-AP-1120 | Med | Medulloblastoma | 0.904 |
| 5 | MDT-AP-0373 | Med | Medulloblastoma | 0.892 |
| 6 | MDT-AP-1115 | Med | Medulloblastoma | 0.888 |
| 7 | MDT-AP-0153 | Med | Medulloblastoma | 0.886 |
| 8 | SRR1404168 | GTEX | — | 0.884 |
| 9 | MBCProject_0719_T1_RNA | — | A | 0.880 |
| 10 | MDT-AP-0808 | Med | Medulloblastoma | 0.879 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 4 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.280 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |